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Abstract
Cardiovascular effects of microinjections of endomorphin-2 into the medial 
subnucleus of the nucleus tractus solitarius (mNTS) were studied in adult, 
male, urethane-anesthetized, Wistar rats. Microinjections of endomorphin-2 
into the mNTS elicited depressor and bradycardic responses via mu-opioid 
receptors. Similar microinjections of endomorphin-2 attenuated the carotid 
sinus and aortic baroreflex responses. Endomorphin-2 inhibits GABAergic 
mNTS neurons via mu-opioid receptors, causing disinhibition which results 
in excitation of secondary mNTS neurons. This effect causes depressor and 
bradycardic responses. Endomorphin-2 also inhibits glutamate release 
from baroreceptor terminals via mu-opioid receptors located on these 
terminals and attenuates baroreflex responses. [Tzu Chi Med J 2008;20(2):
77–81]
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1. Introduction
The role of the medial subnucleus of the nucleus trac-
tus solitarius (mNTS) in cardiovascular regulation is 
well established [1,2]. Peripheral afferents (e.g., barore-
ceptor, cardiopulmonary and chemoreceptor afferents) 
are known to make their primary synapse in this sub-
nucleus. Although there is a general consensus that 
glutamate is the neurotransmitter for regulating car-
diovascular function in the mNTS [2,3], the presence 
of several other substances has been demonstrated 
in this region. Among these substances are endomor-
phins (two tetrapeptides, endomorphin-1 and -2) that 
were isolated from human and bovine brains [4,5]. 
These peptides have been reported to possess a high 
affinity and selectivity for the mu-opioid receptors and 
are considered to be endogenous ligands for these 
receptors [4,5]. The presence of mu-opioid receptors 
[6–8] and endomorphins [9,10] in the mNTS has been 
reported. These reports have prompted investigations 
on the role of endomorphins in the mNTS in cardio-
vascular regulation [11,12].
2. Cardiovascular responses to 
endomorphin in the mNTS
In urethane-anesthetized (1.2–1.4 g/kg, i.v.), artificially 
ventilated, adult, male Wistar rats, microinjections of 
L-glutamate (L-Glu) into the mNTS (0.5–0.6 mm ros-
tral and 0.5–0.6 mm lateral to the calamus scripto-
rius and 0.5–0.6 mm ventral to the dorsal surface of 
the medulla) were used to identify mNTS in all experi-
ments. L-Glu (5 mmol/L) elicited decreases in mean 
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arterial pressure (MAP; 35–45 mmHg) and heart rate 
(HR; 30–40 beats/min); L-Glu stimulates neuronal cell 
bodies but not fibers of passage indicating that the 
cardiovascular responses were mediated by neurons 
in the mNTS. A 100 nL volume elicited maximum re-
sponses; this volume was selected for all microinjec-
tions unless indicated otherwise. Microinjections of 
endomorphin-2 (0.1, 0.2, 0.5, 1, 2 and 4 mmol/L) into 
the mNTS (n= 30) elicited decreases in MAP (25 ± 5.3, 
40± 2.8, 30 ± 3.1, 16.6 ± 4.5, 18 ± 3.4, and 15 ± 1.5 mmHg, 
respectively) and HR (20 ± 3.2, 50 ± 7.0, 37.5 ± 10.3, 
33.3± 8.8, 20 ± 10.0, and 15 ± 2.9 beats/min, respec-
tively). Maximal depressor and bradycardic responses 
were elicited by a 0.2 mmol/L concentration. The onset 
and durations of the responses to microinjections of 
endomorphin-2 (0.2 mmol/L) were 5–10 seconds and 
8–10 minutes, respectively, and the peak effect was 
observed at 2–3 minutes. When the concentrations 
of endomorphin-2 that elicited depressor and brady-
cardic responses in the mNTS (e.g., 0.2 mmol/L) were 
injected intravenously, no responses were elicited, 
indicating that the leakage of endomorphin-2 from 
the microinjection site to the peripheral circulation was 
not responsible for the observed responses. Repeated 
microinjections of endomorphin-2 (0.2 mmol/L) into 
the mNTS did not exhibit tachyphylaxis when the 
interval between injections was at least 20 minutes. 
The possibility that the cardiovascular responses elic-
ited by microinjections of endomorphin-2 into the 
mNTS may have resulted due to the spread of the in-
jected peptide to adjacent regions was excluded by 
microinjecting the peptide into sites adjacent to this 
nucleus (e.g., cuneate nucleus); endomorphin-2 did 
not elicit a response at these sites. Microinjections 
(100 nL) of artificial cerebrospinal fluid (aCSF) into 
the mNTS did not elicit any response, indicating that 
local distortion of brain tissue was not responsible 
for the endomorphin-2 induced responses [12].
3. Effect of vagotomy on endomorphin-
induced bradycardia
Bilateral vagotomy abolished the bradycardia elicited 
by microinjections of endomorphin-2 (0.2 mmol/L) into 
the mNTS while the decreases in MAP remained un-
altered, indicating that the bradycardic responses to 
microinjections of endomorphin-2 into the mNTS were 
mediated predominantly via the vagus nerves [12].
4. Role of mu-opioid receptors in 
mediating endomorphin responses
Naloxonazine (1 mmol/L) was used to demonstrate 
that the responses to endomorphin-2 were mediated 
via mu-1 opioid receptors [13]. Microinjection of 
endomorphin-2 (0.2 mmol/L) into the mNTS elicited 
decreases in MAP and HR. Twenty minutes after re-
covery of the responses, naloxonazine (1 mmol/L) was 
microinjected at the same site. Microinjection of nal-
oxonazine alone elicited no cardiovascular responses. 
Two minutes after the microinjection of naloxonazine, 
microinjection of endomorphin-2 failed to elicit any 
response. The lack of response to endomorphin-2 was 
not due to tachyphylaxis because repeated micro-
injections of endomorphin-2 did not exhibit tachy-
phylaxis as described earlier. A lower concentration 
(0.5 mmol/L) of naloxonazine did not significantly block 
the responses to endomorphin-2 (0.2 mmol/L). That 
naloxonazine did not exert any deleterious effects at 
the site of injection was indicated by the observa-
tion that this antagonist did not alter the depressor 
and bradycardic responses to microinjections of L-
Glu (5 mmol/L) injected 2 minutes after endomorphin-
2 [12].
5. Effect of GABA receptor blockade on 
endomorphin-induced responses
In these experiments, microinjections of endomorphin-
2 (0.2 mmol/L) into the mNTS elicited usual depres-
sor and bradycardic responses. These responses 
were abolished by prior combined microinjections of 
gabazine (2 mmol/L; GABAA receptor antagonist) and 
2-hydroxysaclofen (100 mmol/L; GABAB receptor an-
tagonist). Gabazine and 2-hydroxysaclofen did not alter 
the responses to microinjections of L-Glu into the 
mNTS [12].
6. Effect of glutamate receptor 
blockade on endomorphin-
induced responses
The depressor and bradycardic responses to micro-
injections of endomorphin-2 (0.2 mmol/L) into the 
mNTS were completely blocked by prior combined 
micro injections of NBQX (2 mmol/L; non-NMDA recep-
tor antagonist) and DAP-7 (5 mmol/L; NMDA receptor 
antagonist). Combined microinjections of NBQX and 
D-AP7 did not alter the depressor and bradycardic re-
sponses to an unrelated agonist carbachol (0.5 mmol/L; 
cholinergic receptor agonist) [12].
7. Effect of endomorphin on single 
neurons
The basal firing rate of mNTS neurons, recorded 
extracellularly using glass micropipettes, was 15.9 ±
2.2 spikes/sec. An intravenous bolus injection of 
phenylephrine (3 µg/kg) increased MAP (40 ± 4.8 mmHg) 
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and increased neuronal firing in the mNTS, indicat-
ing that the neuron was involved in baroreflex and, 
therefore, cardiovascular regulation. When the MAP 
returned to basal level, L-Glu (5 mmol/L) was applied 
to the neurons; the ejection volume of all direct ap-
plications of different agents on neurons was 2–4 nL. 
Application of L-Glu increased the neuronal firing, 
indicating that the recording was from a neuron and 
not a fiber of passage. Application of aCSF did not 
elicit a response, indicating that pressure applications 
alone were not responsible for the changes in neuro-
nal firing. Application of endomorphin-2 (0.2 mmol/L) 
increased the firing of the mNTS neurons. Application 
of naloxonazine (1 mmol/L) did not alter the neuronal 
firing, however, it blocked the excitatory effect of sub-
sequent application of endomorphin-2. Naloxonazine 
did not alter the responses to direct application of 
L-Glu (5 mmol/L). In other neurons identified similarly, 
combined application of D-AP7 (5 mmol/L) and NBQX 
(2 mmol/L) decreased the basal firing rate. After the 
firing returned to basal level (40–50 sec), subsequent 
application of endomorphin-2 (0.2 mmol/L) failed to 
excite the neuron [12].
8. Endomorphin-induced attenuation of 
baroreflex responses
The carotid sinus was isolated from the general cir-
culation and connected to a perfusion assembly. The 
pressure in the carotid sinus was increased and the 
systemic cardiovascular responses studied before and 
after the microinjections of endomorphin-2 (0.4 mmol/
L) into the mNTS. Microinjections of endomorphin-2 
into the mNTS attenuated the carotid sinus baroreflex 
responses. Recovery from the endomorphin-2-induced 
attenuation of carotid baroreflex was observed within 
20 minutes [14].
In other experiments, the aortic nerve was electri-
cally stimulated and cardiovascular responses stud-
ied before and after microinjection of endomorphin-2 
(0.4 mmol/L) into the mNTS. Microinjections of endo-
morphin-2 into the mNTS attenuated the responses to 
aortic nerve stimulation. Recovery from endomorphin-
2-induced attenuation of aortic baroreflex responses 
was observed within 20 minutes [14].
The role of endogenous opioid receptors in barore-
flex responses was tested using aortic nerve stimu-
lation. Naloxone (0.5 mmol/L) blocked the effects of 
endomorphin-2 (0.4 mmol/L) but not those of L-Glu 
(5 mmol/L), indicating that naloxone at this dose did 
not exert any deleterious effects in the mNTS. Lower 
concentrations of naloxone (e.g., 0.25 mmol/L) did not 
attenuate the cardiovascular responses to endomorphin-
2 (0.4 mmol/L). Blockade of opioid receptors in the 
mNTS by naloxone alone did not alter cardiovascular 
responses to aortic nerve stimulation [14].
9. Conclusions
Microinjections of endomorphin-2 (0.1–4 mmol/L) into 
the mNTS elicited depressor and bradycardic responses. 
Endomorphin-induced bradycardia was mediated via 
the activation of the parasympathetic innervation to 
the heart because bilateral vagotomy completely abol-
ished these responses. Both the depressor and bra-
dycardic responses were mediated via mu-1 opioid 
receptors because naloxonazine, a specific antago-
nist for mu-1 opioid receptors [13], abolished them. 
Microinjections of naloxonazine by itself did not elicit 
any response, suggesting that mu-1 opioid receptors 
in the mNTS are not endogenously active in the rat.
The blockade of GABA receptors in the mNTS 
abolished the depressor and bradycardic responses 
to microinjections of endomorphin-2 into the mNTS. 
Endomorphin-induced depressor and bradycardic re-
sponses were also abolished after the blockade of 
ionotropic glutamate receptors in the mNTS.
Neuronal recording experiments confirmed our 
results obtained in the microinjection studies [12]. 
Excitatory effect of endomorphin-2 on the mNTS neu-
rons was prevented by prior application of naloxona-
zine; naloxonazine by itself did not elicit any response. 
Endomorphin-2-induced excitation of the neurons was 
completely abolished by prior applications of ionotro-
pic glutamate receptor antagonists (D-AP7 and NBQX).
Microinjections of endomorphin-2 into the mNTS 
attenuated the reflex responses (i.e., decrease in BP 
and HR) to the stimulation of carotid sinus and aortic 
baroreceptors [14]. The effects of endomorphin-2 were 
mediated via opioid receptors because prior micro-
injections of naloxone (an opioid receptor antagonist) 
prevented these responses. However, microinjections 
of naloxone alone did not alter the baroreflex re-
sponses, indicating that opioid receptors in the mNTS 
are not normally involved in regulating the baroreflex 
function.
The excitatory effect of microinjections of 
endomorphin-2 on mNTS neurons resulting in de-
pressor and bradycardic responses on the one hand 
and the inhibitory effect of these microinjections on 
baroreflex on the other hand can be reconciled as 
follows. Immunohistochemical studies have demon-
strated the presence of GABAergic neurons [15,16] 
and terminals [17] in the NTS. Glutamatergic nerve 
terminals of peripheral baroreceptor and cardiopul-
monary afferents are also known to make their first 
synapse in the mNTS [1–3]. There is a general consen-
sus that opioid peptides interact with G-protein coupled 
opioid receptors and usually exert inhibitory effects 
on neurons [18–21]. Thus, inhibition of GABAergic 
neurons by endomorphin-2 via mu-1 receptors may 
result in preponderance of glutamatergic input to the 
secondary mNTS neurons. This may be the reason why 
endomorphin-2-induced depressor and bradycardic 
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responses were no longer observed after GABA re-
ceptor blockade. Furthermore, blockade of ionotropic 
receptors also resulted in the abolition of endomorphin-
2-induced depressor and bradycardic responses.
The attenuation of baroreflex responses by endo-
morphin-2 can be explained by either endomorphin-2-
induced reduction in responses of postsynaptic mNTS 
neurons involved in baroreflex or inhibition of neu-
rotransmitter release from the baroreceptor terminals. 
Reduction in the postsynaptic responses of the neu-
rons involved in baroreflex does not seem to be the 
mechanism by which attenuation of baroreflex is elic-
ited by endomorphin-2 because the responses to 
microinjections of NMDA, which acts predominantly 
postsynaptically [22], remained unaltered after micro-
injections of endomorphin-2 into the mNTS. Therefore, 
attenuation of baroreflex responses by endomorphin-
2 may be ascribed to a reduction in the release of neu-
rotransmitter from the baroreceptor terminals. Since 
glutamate has been reported to be the neurotrans-
mitter released from baroreceptor terminals in the 
mNTS [3], endomorphin-2 may inhibit its release by 
a presynaptic action. In this context, it may be pointed 
out that opioid receptors have been reported to be 
present on presynaptic terminals of vagal afferents in 
the NTS [23] and opioid peptides have been shown to 
inhibit glutamate release from nerve terminals [8, 24–
26]. For this explanation to be true, opioid receptors 
must be present either exclusively or preponderantly on 
the glutamatergic baroreceptor terminals. Supporting 
this hypothesis is the report in which only 33% of the 
vagal afferents contained labeling for opioid receptors, 
suggesting that many glutamatergic terminals in the 
mNTS do not contain opioid receptors [7,23].
Since microinjections of naloxone and naloxona-
zine alone into the mNTS did not exert any cardio-
vascular effects, it is unlikely that endomorphins play 
a role in the regulation of cardiovascular function under 
normal circumstances. However, opioidergic mecha-
nisms may come into play in yet unidentified situations 
which affect cardiovascular function. For example, opi-
oidergic mechanisms may be activated during stress-
ful situations which elicit pressor and tachycardic 
responses. Under these conditions, depressor and 
bradycardic responses elicited by endomorphin in the 
mNTS may mitigate stress-induced pressor and tachy-
cardic responses. Inhibition of baroreflex in such sit-
uations would also be useful because fully functional 
baroreflex would impede compensatory cardiovascular 
adjustments to stressful stimuli.
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